DeepMed Research

Gannex Pharma Co.,Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Healthy and Obese Subjects

Phase 1

Completed

Conditions: Chronic Weight Management

Interventions: Drug: ASC47
Drug: Matching placebo

First Posted Date: 2024-05-24

Last Posted Date: 2025-05-11

Lead Sponsor: Gannex Pharma Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT06427590

Locations: 🇦🇺
Ascletis, Herston, Queensland, Australia

Drug Interaction Study of ASC42 With Atorvastatin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Atorvastatin
Drug: ASC42

First Posted Date: 2022-07-19

Last Posted Date: 2024-04-03

Lead Sponsor: Gannex Pharma Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT05464628

Locations: 🇺🇸
ICON, San Antonio, Texas, United States

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Phase 2

Active, not recruiting

Conditions: Non-alcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease

Interventions: Drug: 2mg of ASC41
Drug: 4mg of ASC41 (2 tablets of 2 mg ASC41)
Drug: Placebo

First Posted Date: 2022-07-18

Last Posted Date: 2025-01-08

Lead Sponsor: Gannex Pharma Co., Ltd.

Target Recruit Count: 183

Registration Number: NCT05462353

Locations: 🇨🇳
The affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: ASC61 400 mg
Drug: ASC61 600 mg
Drug: ASC61 200 mg 2
Drug: ASC61 200 mg 1
Drug: ASC61 300 mg

First Posted Date: 2022-03-18

Last Posted Date: 2024-04-03

Lead Sponsor: Gannex Pharma Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT05287399

Locations: 🇺🇸
California Cancer Associates for Research & Excellence (cCARE), San Marcos, California, United States
🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Phase 2

Completed

Conditions: Primary Biliary Cholangitis

Interventions: Drug: ASC42 15 mg
Drug: Placebo
Drug: ASC42 5 mg
Drug: ASC42 10 mg

First Posted Date: 2022-01-13

Last Posted Date: 2024-04-04

Lead Sponsor: Gannex Pharma Co., Ltd.

Target Recruit Count: 98

Registration Number: NCT05190523

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: ASC43F

First Posted Date: 2021-11-12

Last Posted Date: 2021-12-20

Lead Sponsor: Gannex Pharma Co., Ltd.

Target Recruit Count: 8

Registration Number: NCT05118516

Locations: 🇺🇸
8307 Gault Lane, San Antonio, Texas, United States

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

Phase 2

Withdrawn

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: ASC41 2 mg
Drug: Placebo
Drug: ASC41 4 mg

First Posted Date: 2021-11-12

Last Posted Date: 2023-03-01

Lead Sponsor: Gannex Pharma Co., Ltd.

Registration Number: NCT05118360

DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

Phase 1

Completed

Conditions: Healthy
NAFLD

Interventions: Drug: ASC41
Drug: Itraconazole
Drug: Phenytoin

First Posted Date: 2021-04-15

Last Posted Date: 2021-07-19

Lead Sponsor: Gannex Pharma Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT04845646

Locations: 🇺🇸
ICON early Phase Services LLC, San Antonio, Texas, United States

Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers

Phase 1

Completed

Conditions: Hyperlipidemia
Healthy
NAFLD

Interventions: Drug: ASC41 tablet

First Posted Date: 2020-12-31

Last Posted Date: 2021-04-08

Lead Sponsor: Gannex Pharma Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT04692025

Locations: 🇨🇳
Hunan provincial people's hospital, Changsha, Hunan, China

Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

Phase 1

Completed

Conditions: Overweight and Obesity
NAFLD
Hyperlipidemia

Interventions: Drug: ASC 41
Drug: ASC 41 Placebo

First Posted Date: 2020-12-29

Last Posted Date: 2024-09-27

Lead Sponsor: Gannex Pharma Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT04686994

Locations: 🇨🇳
Hunan provincial people's hospital, Changsha, Hunan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy